Immune Dynamics of Pathological Complete Response to Neoadjuvant Immunotherapy in Hepatocellular Carcinoma: Mechanisms, Biomarkers, and Prognostic Implications
- 1Department of General Surgery, Chaoyang City Center Hospital of China Medical University, Chaoyang, Liaoning, People’s Republic of China
Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, with 5-year postoperative recurrence rates as high as 70%, severely limiting long-term survival after surgical resection. The success of immune checkpoint inhibitors in advanced HCC has driven their expansion into the neoadjuvant setting, where pathological complete response (pCR) has emerged as a potential endpoint associated with improved outcomes, although its validation as a surrogate for overall survival requires further prospective evidence. This review systematically synthesizes current evidence on the immune dynamics underlying pCR following neoadjuvant immunotherapy in HCC. Pooled analyses report pCR rates of approximately 18–24%, while certain intensive regimens, such as dual immune checkpoint inhibitor combinations, have achieved rates up to 41% in selected populations, albeit with increased toxicity. The peripheral infiltration and expansion of high-frequency intratumoral T-cell clonotypes are associated with pathological response, although a causal relationship remains to be established. Baseline tumor-infiltrating lymphocyte density, tertiary lymphoid structures, and dynamic changes in circulating tumor DNA are emerging as promising predictive biomarkers. In pan-tumor analyses, patients achieving pCR demonstrate substantially improved relapse-free survival, with 3-year event-free survival rates ranging from 78.6% to 100%; however, HCC-specific prospective data remain limited. However, heterogeneity in pCR definitions, lack of standardized pathological assessment, and limited long-term follow-up data constrain the definitive qualification of pCR as a surrogate endpoint. Future directions include standardization of pCR assessment, multi-omics integration for improved prediction, biomarker-guided patient selection, and large-scale prospective validation. This review provides a comprehensive framework for understanding the immune mechanisms of pCR and its clinical implications, offering guidance for clinicians and researchers in the evolving landscape of neoadjuvant immunotherapy for HCC.
Related
- Spatial immune remodeling during neoadjuvant therapy in hepatocellular carcinoma: Mechanisms, clinical implications, and future perspectives
- Prediction of pathological complete response to neoadjuvant chemo-immunotherapy in locally advanced lung adenocarcinoma: a multimodal machine learning approach
- Prediction of Pathological Complete Response to Neoadjuvant Immunotherapy-Based Regimens for Non-Metastatic Colon and Rectal Cancer
- Pathological complete response and major pathological response as surrogate endpoints for recurrence-free survival in perioperative immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis
- Macrophages in T cell-mediated rejection of renal allografts: pathological mechanisms and CAR-macrophage immunotherapy
BibTeX
@article{ling2026immune,
title = {{Immune Dynamics of Pathological Complete Response to Neoadjuvant Immunotherapy in Hepatocellular Carcinoma: Mechanisms, Biomarkers, and Prognostic Implications}},
author = {Yunzhi Ling and Guoming Li and Yijun Liu and Weijun Li and Yantao Fu},
journal = {Journal of Hepatocellular Carcinoma},
year = {2026},
month = nov,
doi = {10.2147/jhc.s651068},
url = {https://doi.org/10.2147/jhc.s651068},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Immune Dynamics of Pathological Complete Response to Neoadjuvant Immunotherapy in Hepatocellular Carcinoma: Mechanisms, Biomarkers, and Prognostic Implications
AU - Yunzhi Ling
AU - Guoming Li
AU - Yijun Liu
AU - Weijun Li
AU - Yantao Fu
PY - 2026
DA - 2026/11/05
JO - Journal of Hepatocellular Carcinoma
DO - 10.2147/jhc.s651068
UR - https://doi.org/10.2147/jhc.s651068
AB - Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, with 5-year postoperative recurrence rates as high as 70%, severely limiting long-term survival after surgical resection. The success of immune checkpoint inhibitors in advanced HCC has driven their expansion into the neoadjuvant setting, where pathological complete response (pCR) has emerged as a potential endpoint associated with improved outcomes, although its validation as a surrogate for overall survival requires further prospective evidence. This review systematically synthesizes current evidence on the immune dynamics underlying pCR following neoadjuvant immunotherapy in HCC. Pooled analyses report pCR rates of approximately 18–24%, while certain intensive regimens, such as dual immune checkpoint inhibitor combinations, have achieved rates up to 41% in selected populations, albeit with increased toxicity. The peripheral infiltration and expansion of high-frequency intratumoral T-cell clonotypes are associated with pathological response, although a causal relationship remains to be established. Baseline tumor-infiltrating lymphocyte density, tertiary lymphoid structures, and dynamic changes in circulating tumor DNA are emerging as promising predictive biomarkers. In pan-tumor analyses, patients achieving pCR demonstrate substantially improved relapse-free survival, with 3-year event-free survival rates ranging from 78.6% to 100%; however, HCC-specific prospective data remain limited. However, heterogeneity in pCR definitions, lack of standardized pathological assessment, and limited long-term follow-up data constrain the definitive qualification of pCR as a surrogate endpoint. Future directions include standardization of pCR assessment, multi-omics integration for improved prediction, biomarker-guided patient selection, and large-scale prospective validation. This review provides a comprehensive framework for understanding the immune mechanisms of pCR and its clinical implications, offering guidance for clinicians and researchers in the evolving landscape of neoadjuvant immunotherapy for HCC.
SN - 2253-5969
ER -